Ab­b­Vie in po­si­tion to be­come largest phar­ma by 2028, nar­row­ly edg­ing out Roche — re­port

Thanks to the suc­cess of its Covid-19 vac­cine Comir­naty, Pfiz­er cur­rent­ly holds the top spot in Eval­u­ate Phar­ma’s rank­ing of phar­ma com­pa­nies by sales — but not for long, ac­cord­ing to an­a­lysts.

A new Eval­u­ate Phar­ma re­port pre­dicts that Pfiz­er will drop down four spots by 2028, with Ab­b­Vie pegged to be­come the top-sell­ing phar­ma with an es­ti­mat­ed $65.7 bil­lion in sales.

De­spite ap­proach­ing a fast-ap­proach­ing patent cliff for Hu­mi­ra, Ab­b­Vie has can­di­dates in the pipeline to re­place that lost rev­enue, such as Skyrizi, Rin­voq and Ven­clex­ta, ac­cord­ing to an­a­lysts. CEO Rick Gon­za­lez picked up on that note ear­li­er this year when he pre­dict­ed Skyrizi and Rin­voq will be­come Hu­mi­ra’s suc­ces­sors, tak­ing up all of its in­di­ca­tions plus atopic der­mati­tis.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN